



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Ryuichi Morishita et al.

Application No. 09/869,475

Filed: October 10, 2001

Confirmation No. 4309

For: GENE THERAPY FOR DIABETIC
ISCHEMIC DISEASE

Examiner: Brian Whiteman

Art Unit: 1635

Attorney Reference No. 6235-59221-01

CERTIFICATE OF MAILING

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450 on the date shown below.

Agent
for Applicant(s)

Date Mailed

3/14/05

COMMISSIONER FOR PATENTS
P.O. BOX 1450
ALEXANDRIA, VA 22313-1450

considered
6/10/05

DECLARATION OF RYUICHI MORISHITA AND
TOSHIO OGIHARA UNDER 37 C.F.R. §1.132 AND MPEP §2132.01

We, RYUICHI MORISHITA and TOSHIO OGIHARA declare as follows:

1. We are two of the co-inventors of, and have each read and understand, U.S. Patent No. 6,248,722 entitled MEDICAMENT COMPRISING HGF GENE (hereinafter the '722 patent), which issued June 19, 2001.

2. We are named co-inventors of, and have each read and understand, U.S. Patent Application No. 09/869,475 (hereinafter the '475 application) entitled GENE THERAPY FOR DIABETIC ISCHEMIC DISEASE. Claims 9, 11, 12, 14, 23-26, 28-34, and 36-42 were rejected as allegedly being anticipated (under 35 U.S.C. §102(e)) by the teachings of the '722 patent.